197 related articles for article (PubMed ID: 19184019)
1. Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine.
Noble CO; Guo Z; Hayes ME; Marks JD; Park JW; Benz CC; Kirpotin DB; Drummond DC
Cancer Chemother Pharmacol; 2009 Sep; 64(4):741-51. PubMed ID: 19184019
[TBL] [Abstract][Full Text] [Related]
2. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
[TBL] [Abstract][Full Text] [Related]
3. Liposome-encapsulated vincristine, vinblastine and vinorelbine: a comparative study of drug loading and retention.
Zhigaltsev IV; Maurer N; Akhong QF; Leone R; Leng E; Wang J; Semple SC; Cullis PR
J Control Release; 2005 May; 104(1):103-11. PubMed ID: 15866338
[TBL] [Abstract][Full Text] [Related]
4. Tumor targeting using anti-her2 immunoliposomes.
Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC
J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487
[TBL] [Abstract][Full Text] [Related]
5. Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties.
Krishna R; Webb MS; St Onge G; Mayer LD
J Pharmacol Exp Ther; 2001 Sep; 298(3):1206-12. PubMed ID: 11504822
[TBL] [Abstract][Full Text] [Related]
6. Future directions of liposome- and immunoliposome-based cancer therapeutics.
Park JW; Benz CC; Martin FJ
Semin Oncol; 2004 Dec; 31(6 Suppl 13):196-205. PubMed ID: 15717745
[TBL] [Abstract][Full Text] [Related]
7. Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments.
Sapra P; Moase EH; Ma J; Allen TM
Clin Cancer Res; 2004 Feb; 10(3):1100-11. PubMed ID: 14871990
[TBL] [Abstract][Full Text] [Related]
8. Development of a highly stable and targetable nanoliposomal formulation of topotecan.
Drummond DC; Noble CO; Guo Z; Hayes ME; Connolly-Ingram C; Gabriel BS; Hann B; Liu B; Park JW; Hong K; Benz CC; Marks JD; Kirpotin DB
J Control Release; 2010 Jan; 141(1):13-21. PubMed ID: 19686789
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo.
Mamot C; Drummond DC; Noble CO; Kallab V; Guo Z; Hong K; Kirpotin DB; Park JW
Cancer Res; 2005 Dec; 65(24):11631-8. PubMed ID: 16357174
[TBL] [Abstract][Full Text] [Related]
10. Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes.
Sapra P; Allen TM
Clin Cancer Res; 2004 Apr; 10(7):2530-7. PubMed ID: 15073133
[TBL] [Abstract][Full Text] [Related]
11. Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations.
Johnston MJ; Semple SC; Klimuk SK; Edwards K; Eisenhardt ML; Leng EC; Karlsson G; Yanko D; Cullis PR
Biochim Biophys Acta; 2006 Jan; 1758(1):55-64. PubMed ID: 16487476
[TBL] [Abstract][Full Text] [Related]
12. Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs.
Huang ZR; Tipparaju SK; Kirpotin DB; Pien C; Kornaga T; Noble CO; Koshkaryev A; Tran J; Kamoun WS; Drummond DC
J Control Release; 2019 Sep; 310():47-57. PubMed ID: 31400383
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells.
Roth A; Drummond DC; Conrad F; Hayes ME; Kirpotin DB; Benz CC; Marks JD; Liu B
Mol Cancer Ther; 2007 Oct; 6(10):2737-46. PubMed ID: 17938267
[TBL] [Abstract][Full Text] [Related]
14. Development of a stable single-vial liposomal formulation for vincristine.
Mao W; Wu F; Lee RJ; Lu W; Wang J
Int J Nanomedicine; 2019; 14():4461-4474. PubMed ID: 31296986
[No Abstract] [Full Text] [Related]
15. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models.
Webb MS; Harasym TO; Masin D; Bally MB; Mayer LD
Br J Cancer; 1995 Oct; 72(4):896-904. PubMed ID: 7547237
[TBL] [Abstract][Full Text] [Related]
16. The effect of vincristine-polyanion complexes in STEALTH liposomes on pharmacokinetics, toxicity and anti tumor activity.
Zhu G; Oto E; Vaage J; Quinn Y; Newman M; Engbers C; Uster P
Cancer Chemother Pharmacol; 1996; 39(1-2):138-42. PubMed ID: 8995511
[TBL] [Abstract][Full Text] [Related]
17. The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib.
Korani M; Nikoofal-Sahlabadi S; Nikpoor AR; Ghaffari S; Attar H; Mashreghi M; Jaafari MR
Anticancer Agents Med Chem; 2020; 20(6):700-708. PubMed ID: 31893998
[TBL] [Abstract][Full Text] [Related]
18. Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage.
Shmeeda H; Tzemach D; Mak L; Gabizon A
J Control Release; 2009 Jun; 136(2):155-60. PubMed ID: 19331844
[TBL] [Abstract][Full Text] [Related]
19. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
Kirpotin DB; Drummond DC; Shao Y; Shalaby MR; Hong K; Nielsen UB; Marks JD; Benz CC; Park JW
Cancer Res; 2006 Jul; 66(13):6732-40. PubMed ID: 16818648
[TBL] [Abstract][Full Text] [Related]
20. Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer.
Webb MS; Logan P; Kanter PM; St-Onge G; Gelmon K; Harasym T; Mayer LD; Bally MB
Cancer Chemother Pharmacol; 1998; 42(6):461-70. PubMed ID: 9788572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
